Avalo Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGAvalo Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 31), showing significant lag compared to the market leaders. Earnings contraction of 105% provides fundamental context to the price action. However, price is extended 42% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $14.44 | +51.00% | ABOVE |
| 50 SMA | $15.34 | +42.14% | ABOVE |
| 100 SMA | $15.85 | +37.63% | ABOVE |
| 150 SMA | $16.03 | +36.09% | ABOVE |
| 200 SMA | $14.41 | +51.35% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AVTX in an uptrend right now?
AVTX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is AVTX overbought or oversold?
AVTX's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.
Is AVTX outperforming the market?
AVTX has a Relative Strength (RS) Rating of 31 out of 99. AVTX is currently lagging the broader market.
Where is AVTX in its 52-week range?
AVTX is trading at $21.81, which is 92% of its 52-week high ($23.71) and 91% above its 52-week low ($3.39).
How volatile is AVTX?
AVTX has a Beta of 1.21 and 52-week volatility of 83%. It's more volatile than the S&P 500 - expect bigger swings.